Citations

Clear

4801 citation(s) found for "Yu, Jennifer".

The role of preoperative optimization of the nutritional status on the improvement of short‐term outcomes after liver transplantation? A review of the literature and expert panel recommendations
Victor, David W. , Towey, Jennifer , Spiro, Michael , Burra, Patrizia , Group, the ERAS4OLT.org Working, Zanetto, Alberto , Montaño‐Loza, Aldo J. , Heimbach, Julie K. , Raptis, Dimitri , Group, the ERAS4OLT.org Working, Tinguely, Pascale

Mayo Clinic

Clinical Transplantation | March 18, 2022 | Volume: 36 | Issue: 10 | Pages: No page available

10.1111/ctr.14647 | PMID 35303370 Get It

AbstractBackgroundMalnutrition is a known risk factor for postoperative morbidity and mortality in patients awaiting liver transplantation (LT). Malnutrition is a potentially reversible risk factor, though there are no clear guidelines on the best mechanism for an improvement. It also remains unclear if preoperative nutritional interventions have benefits to post‐transplant outcomes for transplant recipients.ObjectivesPrimary objective: To identify if preoperative optimization of nutritional status is associated with improved short‐term outcomes after LT. Secondary Objectives: To determine if preoperative improvement of malnutrition improves short‐term outcomes after LT, as well as if weight loss in obese patients affects short‐term outcomes after LT.Data sourcesOvid MEDLINE, Embase, Scopus, Google Scholar, and Cochrane Central.MethodsSystematic review following PRISMA guidelines and recommendations using the GRADE approach derived from an international expert panel. POSPERO Protocol ID: CRD42021237450Results3851 records were identified in searching the databases, 3843 records were excluded by not fulfilling eligibility criteria. Seven full‐text articles were included for the final analysis of which three were randomized controlled trials, one was prospective observational studies, and three were retrospective observational studies. No appreciable difference in mortality, post‐transplant complication rate was noted across the studies. Length of stay (LOS) was noted to be shorter in two observational studies of Vitamin D deficiency in liver transplant patients.ConclusionsWe have made a weak recommendation supporting pre‐transplant nutritional supplementation due to possible benefit in reducing LOS as well as the lack of harm (Quality of Evidence low | Grade of Recommendation; Weak). No effective conclusions were reached for the secondary objectives due to the conflicting evidence.
American College of Gastroenterology-Canadian Association of Gastroenterology Clinical Practice Guideline: Management of Anticoagulants and Antiplatelets During Acute Gastrointestinal Bleeding and the Periendoscopic Period
Abraham, Neena S. , Douketis, James D. , Laine, Loren , Telford, Jennifer J. , Telford, Jennifer J , Barkun, Alan , Sauer, Bryan G. , Noseworthy, Peter A. , Leontiadis, Grigorios I.

Mayo Clinic

Journal of the Canadian Association of Gastroenterology | March 17, 2022 | Volume: 5 | Issue: 2 | Pages: 100-101

10.1093/jcag/gwac010 | PMID 35368325 Get It

AbstractWe conducted systematic reviews of predefined clinical questions and used the Grading of Recommendations, Assessment, Development and Evaluations approach to develop recommendations for the periendoscopic management of anticoagulant and antiplatelet drugs during acute gastrointestinal (GI) bleeding and the elective endoscopic setting. The following recommendations target patients presenting with acute GI bleeding: For patients on warfarin, we suggest against giving fresh frozen plasma or vitamin K; if needed, we suggest prothrombin complex concentrate (PCC) compared with fresh frozen plasma administration; for patients on direct oral anticoagulants (DOACs), we suggest against PCC administration; if on dabigatran, we suggest against the administration of idarucizumab, and if on rivaroxaban or apixaban, we suggest against andexanet alfa administration; for patients on antiplatelet agents, we suggest against platelet transfusions; and for patients on cardiac acetylsalicylic acid (ASA) for secondary prevention, we suggest against holding it, but if the ASA has been interrupted, we suggest resumption on the day hemostasis is endoscopically confirmed. The following recommendations target patients in the elective (planned) endoscopy setting: For patients on warfarin, we suggest continuation as opposed to temporary interruption (1–7 days), but if it is held for procedures with high risk of GI bleeding, we suggest against bridging anticoagulation unless the patient has a mechanical heart valve; for patients on DOACs, we suggest temporarily interrupting rather than continuing these; for patients on dual antiplatelet therapy for secondary prevention, we suggest temporary interruption of the P2Y12 receptor inhibitor while continuing ASA; and if on cardiac ASA monotherapy for secondary prevention, we suggest against its interruption. Evidence was insufficient in the following settings to permit recommendations. With acute GI bleeding in patients on warfarin, we could not recommend for or against PCC administration when compared with placebo. In the elective periprocedural endoscopy setting, we could not recommend for or against temporary interruption of the P2Y12 receptor inhibitor for patients on a single P2Y12 inhibiting agent. We were also unable to make a recommendation regarding same-day resumption of the drug vs 1–7 days after the procedure among patients prescribed anticoagulants (warfarin or DOACs) or P2Y12 receptor inhibitor drugs because of insufficient evidence.
Posterior cortical atrophy: Primary occipital variant
Shir, Dror , Graff‐Radford, Jonathan , Pham, Nha Trang Thu, Jack, Clifford R. , Lowe, Val J. , Whitwell, Jennifer L. , Josephs, Keith A. , Whitwell, Jennifer , Josephs, Keith A , Jack, Clifford R , Shir, Dror , Machulda, Mary M.

Mayo Clinic

European Journal of Neurology | March 17, 2022 | Volume: 29 | Issue: 7 | Pages: 2138-2143

10.1111/ene.15327 | PMID 35298068 Get It

AbstractBackgroundPosterior cortical atrophy (PCA) is one of the atypical Alzheimer's disease variants, characterized by predominant visuospatial and visuoperceptual deficits, with established dorsal and ventral subtypes. A third primary occipital (caudal) variant has been suggested. We aimed to determine its demographics, clinical manifestations, and biomarker findings.MethodsFifty‐two PCA patients were investigated. Patients underwent neuropsychological assessment, magnetic resonance imaging, and fluorodeoxyglucose (FDG)‐, amyloid‐, and tau‐positron emission tomography (tau‐PET) scans. Normalized regional FDG‐PET values were represented as z‐scores relative to a control population. Patients were divided into “primary occipital” and “other PCA” subgroups according to FDG‐PET‐defined criteria, with primary occipital defined as patients in which the z‐scores for occipital subregions were at least one standard deviation lower (SD) (i.e., more abnormal) than the z‐scores in all other brain regions. Global amyloid‐PET, temporo‐parietal FDG‐PET, and temporal tau‐PET regions‐of‐interest (ROIs) were calculated.ResultsNine patients were classified as primary occipital; they were older (p = 0.034) and had more years of education (p = 0.007) than other PCA patients. The primary occipital group performed worse on the Ishihara test for color perception (p < 0.001), while other PCA patients performed worse on the Western Aphasia Battery (WAB) praxis scale (p = 0.005). Overall neuropsychiatric symptom burden was lower in the primary occipital group (p < 0.001). The FDG‐PET meta‐ROI was higher in the primary occipital subtype (p = 0.006), but no differences were observed in amyloid‐ and tau‐PET.ConclusionsOur findings suggest that primary occipital PCA is characterized by an older age at onset, more color perception dysfunction, less severe ideomotor apraxia, and less hypometabolism in temporo‐parietal meta‐ROI compared to established phenotypes.
Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials
Casulo, Carla , Dixon, Jesse G. , Le‐Rademacher, Jennifer , Hoster, Eva , Höchster, Howard S. , Marcus, Robert, Herold, Michael , Sebban, Catherine, Foon, Kenneth A. , Nielsen, Tina, Vitolo, Umberto , Shi, Qian , Flowers, Christopher R. , Gyan, Emmanuel , Vitolo, Umberto , Salles, Gilles A , Le-Rademacher, Jennifer G , Shi, Qian , Casulo, Carla , Hoster, Eva , Dixon, Jesse G , Klapper, Wolfram , Marcus, Robert, Kimby, Eva , Gyan, Emmanuel , Salles, Gilles

Mayo Clinic

Blood | March 17, 2022 | Volume: 139 | Issue: 11 | Pages: 1684-1693

10.1182/blood.2020010263 | PMID 34614146 Get It

Abstract Observational studies and stand-alone trials indicate that patients with follicular lymphoma (FL) who experience disease progression within 24 months of front-line chemoimmunotherapy (POD24), have poor outcomes. We performed a pooled analysis of 13 randomized clinical trials of patients with FL in the pre- and postrituximab eras to identify clinical factors that predict POD24. Logistic regression models evaluated the association between clinical factors and POD24. Cox regression evaluated the association between POD24 as a time-dependent factor and subsequent overall survival (OS). A landmark analysis evaluated the association of POD24 with OS for the subset of patients who were alive at 24 months after trial registration. Patients without progression at 24 months at baseline had favorable performance status (PS), limited-stage (I/II) disease, low-risk FL International Prognostic Index (FLIPI) score, normal baseline hemoglobin, and normal baseline β2 microglobulin (B2M) level. In a multivariable logistic regression model, male sex (odds ratio [OR], 1.30), PS ≥2 (OR, 1.63), B2M (≥3 mg/L; OR, 1.43), and high-risk FLIPI score (3-5; OR, 3.14) were associated with increased risk of progression before 24 months. In the time-dependent Cox model and the 24-month landmark analysis, POD24 was associated with poor subsequent OS (hazard ratio, 4.85 and 3.06, respectively). This is the largest pooled analysis of clinical trials data validating POD24 as a robust indicator of poor FL survival and identified clinical predictors of early death and progression that can aid in building comprehensive prognostic models incorporating clinical and molecular predictors of POD24.
American College of Gastroenterology-Canadian Association of Gastroenterology Clinical Practice Guideline: Management of Anticoagulants and Antiplatelets During Acute Gastrointestinal Bleeding and the Periendoscopic Period
Abraham, Neena S. , Barkun, Alan , Sauer, Bryan G. , Douketis, James D. , Laine, Loren , Telford, Jennifer J. , Telford, Jennifer J , Barkun, Alan N , Noseworthy, Peter A. , Leontiadis, Grigorios I.

Mayo Clinic

American Journal of Gastroenterology | March 17, 2022 | Volume: 117 | Issue: 4 | Pages: 542-558

10.14309/ajg.0000000000001627 | PMID 35297395 Get It

We conducted systematic reviews of predefined clinical questions and used the Grading of Recommendations, Assessment, Development and Evaluations approach to develop recommendations for the periendoscopic management of anticoagulant and antiplatelet drugs during acute gastrointestinal (GI) bleeding and the elective endoscopic setting. The following recommendations target patients presenting with acute GI bleeding: For patients on warfarin, we suggest against giving fresh frozen plasma or vitamin K; if needed, we suggest prothrombin complex concentrate (PCC) compared with fresh frozen plasma administration; for patients on direct oral anticoagulants (DOACs), we suggest against PCC administration; if on dabigatran, we suggest against the administration of idarucizumab, and if on rivaroxaban or apixaban, we suggest against andexanet alfa administration; for patients on antiplatelet agents, we suggest against platelet transfusions; and for patients on cardiac acetylsalicylic acid (ASA) for secondary prevention, we suggest against holding it, but if the ASA has been interrupted, we suggest resumption on the day hemostasis is endoscopically confirmed. The following recommendations target patients in the elective (planned) endoscopy setting: For patients on warfarin, we suggest continuation as opposed to temporary interruption (1–7 days), but if it is held for procedures with high risk of GI bleeding, we suggest against bridging anticoagulation unless the patient has a mechanical heart valve; for patients on DOACs, we suggest temporarily interrupting rather than continuing these; for patients on dual antiplatelet therapy for secondary prevention, we suggest temporary interruption of the P2Y 12 receptor inhibitor while continuing ASA; and if on cardiac ASA monotherapy for secondary prevention, we suggest against its interruption. Evidence was insufficient in the following settings to permit recommendations. With acute GI bleeding in patients on warfarin, we could not recommend for or against PCC administration when compared with placebo. In the elective periprocedural endoscopy setting, we could not recommend for or against temporary interruption of the P2Y 12 receptor inhibitor for patients on a single P2Y 12 inhibiting agent. We were also unable to make a recommendation regarding same-day resumption of the drug vs 1–7 days after the procedure among patients prescribed anticoagulants (warfarin or DOACs) or P2Y 12 receptor inhibitor drugs because of insufficient evidence.
Vitamin C Plasma Levels Associated with Inflammatory Biomarkers, CRP and RDW: Results from the NHANES 2003–2006 Surveys
Crook, Jennifer , Horgas, Ann L. , Yoon, Saunjoo L. , Grundmann, Oliver , Johnson‐Mallard, Versie, Crook, Jennifer Marie, Yoon, Saun-Joo

Mayo Clinic

Nutrients | March 16, 2022 | Volume: 14 | Issue: 6 | Pages: 1254

10.3390/nu14061254 | PMID 35334908 Get It

Although undisputed for its anti-inflammatory and immune system boosting properties, vitamin C remains an inconsistently investigated nutrient in the United States. However, subclinical inadequacies may partly explain increased inflammation and decreased immune function within the population. This secondary analysis cross-sectional study used the 2003–2006 NHANES surveys to identify more clearly the association between plasma vitamin C and clinical biomarkers of acute and chronic inflammation C-reactive protein (CRP) and red cell distribution width (RDW). From plasma vitamin C levels separated into five defined categories (deficiency, hypovitaminosis, inadequate, adequate, and saturating), ANOVA tests identified significant differences in means in all insufficient vitamin C categories (deficiency, hypovitaminosis, and inadequate) and both CRP and RDW in 7607 study participants. There were also statistically significant differences in means between sufficient plasma vitamin C levels (adequate and saturating categories) and CRP. Significant differences were not identified between adequate and saturating plasma vitamin C levels and RDW. Although inadequate levels of vitamin C may not exhibit overt signs or symptoms of deficiency, differences in mean levels identified between inflammatory biomarkers suggest a closer examination of those considered at risk for inflammatory-driven diseases. Likewise, the subclinical levels of inflammation presented in this study provide evidence to support ranges for further clinical inflammation surveillance.
Reply to A. Rizzo et al
Gile, Jennifer , Jatoi, Amina, Wee, Wen , Borad, Mitesh J. , Tran, Nguyen H. , Jatoi, Aminah , Ma, Wen Wee , Borad, Mitesh J , Gile, Jennifer Jane , Tran, Nguyen

Mayo Clinic

JCO Precision Oncology | March 16, 2022 | Volume: No volume available | Issue: 6 | Pages: No page available

10.1200/po.22.00061 | PMID 35294225 Get It

Hepatology Highlights
Tomlinson, Jennifer L. , Ahn, Joseph , Povero, Davide , Ramkissoon, Resham­ , Ahn, Joseph C , Tomlinson, Jennifer , Ilyas, Sumera I. , Arab, Juan Pablo

Mayo Clinic

Hepatology | March 15, 2022 | Volume: 75 | Issue: 4 | Pages: 775-776

10.1002/hep.32418 Get It

Evidence for machine learning guided early prediction of acute outcomes in the treatment of depressed children and adolescents with antidepressants
Athreya, Arjun P. , Voort, Jennifer L. Vande , Shekunov, Julia , Rackley, Sandra , Leffler, Jarrod M. , McKean, Alastair J. , Romanowicz, Magdalena , Emslie, Graham J. , Mayes, Taryn L. , Trivedi, Madhukar H. , Wang, Liewei , Weinshilboum, Richard M. , Vande Voort, Jennifer L., Rackley, Sandra J, Bobo, William V. , Mayes, Taryn , Kennard, Betsy D. , Weinshilboum, Richard M. , Croarkin, Paul E.

Mayo Clinic

Journal of Child Psychology and Psychiatry | March 15, 2022 | Volume: 63 | Issue: 11 | Pages: 1347-1358

10.1111/jcpp.13580 | PMID 35288932 Get It

Background The treatment of depression in children and adolescents is a substantial public health challenge. This study examined artificial intelligence tools for the prediction of early outcomes in depressed children and adolescents treated with fluoxetine, duloxetine, or placebo. Methods The study samples included training datasets ( N = 271) from patients with major depressive disorder (MDD) treated with fluoxetine and testing datasets from patients with MDD treated with duloxetine ( N = 255) or placebo ( N = 265). Treatment trajectories were generated using probabilistic graphical models (PGMs). Unsupervised machine learning identified specific depressive symptom profiles and related thresholds of improvement during acute treatment. Results Variation in six depressive symptoms (difficulty having fun, social withdrawal, excessive fatigue, irritability, low self‐esteem, and depressed feelings) assessed with the Children’s Depression Rating Scale‐Revised at 4–6 weeks predicted treatment outcomes with fluoxetine at 10–12 weeks with an average accuracy of 73% in the training dataset. The same six symptoms predicted 10–12 week outcomes at 4–6 weeks in (a) duloxetine testing datasets with an average accuracy of 76% and (b) placebo‐treated patients with accuracies of 67%. In placebo‐treated patients, the accuracies of predicting response and remission were similar to antidepressants. Accuracies for predicting nonresponse to placebo treatment were significantly lower than antidepressants. Conclusions PGMs provided clinically meaningful predictions in samples of depressed children and adolescents treated with fluoxetine or duloxetine. Future work should augment PGMs with biological data for refined predictions to guide the selection of pharmacological and psychotherapeutic treatment in children and adolescents with depression.
A Preliminary Report of Network Electroencephalographic Measures in Primary Progressive Apraxia of Speech and Aphasia
Utianski, Rene L. , Caviness, John N., Duffy, Joseph R. , Clark, Heather M. , Whitwell, Jennifer L. , Josephs, Keith A. , Duffy, Joseph R , Clark, Heather M , Utianski, Rene L , Botha, Hugo , Worrell, Gregory A.

Mayo Clinic

Brain Sciences | March 13, 2022 | Volume: 12 | Issue: 3 | Pages: 378

10.3390/brainsci12030378 | PMID 35326334 Get It

The objective of this study was to characterize network-level changes in nonfluent/agrammatic Primary Progressive Aphasia (agPPA) and Primary Progressive Apraxia of Speech (PPAOS) with graph theory (GT) measures derived from scalp electroencephalography (EEG) recordings. EEGs of 15 agPPA and 7 PPAOS patients were collected during relaxed wakefulness with eyes closed (21 electrodes, 10–20 positions, 256 Hz sampling rate, 1–200 Hz bandpass filter). Eight artifact-free, non-overlapping 1024-point epochs were selected. Via Brainwave software, GT weighted connectivity and minimum spanning tree (MST) measures were calculated for theta and upper and lower alpha frequency bands. Differences in GT and MST measures between agPPA and PPAOS were assessed with Wilcoxon rank-sum tests. Of greatest interest, Spearman correlations were computed between behavioral and network measures in all frequency bands across all patients. There were no statistically significant differences in GT or MST measures between agPPA and PPAOS. There were significant correlations between several network and behavioral variables. The correlations demonstrate a relationship between reduced global efficiency and clinical symptom severity (e.g., parkinsonism, AOS). This preliminary, exploratory study demonstrates potential for EEG GT measures to quantify network changes associated with degenerative speech–language disorders.